Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB1 | P15086 | 2/20 | 0.49 |
| ▸ | HSD11B1 | P28845 | 4/20 | 0.47 |
| ▸ | HSD11B2 | P80365 | 3/20 | 0.47 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2837021 | 1.00 | CPB1 (0.49) | CPB1HSD11B1HSD11B2CYP17A1CYP19A1 | |
| SCHEMBL12578289 | 1.00 | CPB1 (0.49) | CPB1HSD11B1HSD11B2CYP17A1CYP19A1 | |
| SCHEMBL2169834 | 0.91 | CYP17A1 (0.45) | CPB1HSD11B1HSD11B2CYP17A1CYP19A1 | |
| SCHEMBL2825063 | 0.90 | HSD11B1 (0.56) | CPB1HSD11B1HSD11B2EPHX2ALDH1A1 | |
| SCHEMBL1845687 | 0.90 | HSD11B1 (0.56) | CPB1HSD11B1HSD11B2EPHX2ALDH1A1 | |
| SCHEMBL1846642 | 0.90 | HSD11B1 (0.56) | CPB1HSD11B1HSD11B2EPHX2ALDH1A1 | |
| SCHEMBL1846641 | 0.90 | HSD11B1 (0.56) | CPB1HSD11B1HSD11B2EPHX2ALDH1A1 | |
| SCHEMBL12578487 | 0.90 | HSD11B1 (0.56) | CPB1HSD11B1HSD11B2EPHX2ALDH1A1 | |
| SCHEMBL1844036 | 0.87 | HSD11B1 (0.57) | CPB1HSD11B1HSD11B2EPHX2 | |
| SCHEMBL1044166 | 0.87 | HSD11B1 (0.57) | CPB1HSD11B1HSD11B2EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110159019-A1 | 2,4-DIAMINOPYRIMIDINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-06-30 | — | — | US | disclosed |
| EP-2325175-A1 | 2,4-DIAMINOPYRIMIDINE COMPOUND | Astellas Pharma Inc. (JP) | 2011-05-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110159019-A1 | 2,4-DIAMINOPYRIMIDINE COMPOUND | PRKCZ, DCLK1, AAK1 | CPB1 1339/4885HSD11B1 2713/4885HSD11B2 2516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.